Lessons Learned: An Inside Look At Overcoming Stem Cell Therapy Scale-up
By Cellipont Bioservices
With an increased focus in the pharmaceutical industry on addressing unmet medical needs, areas of the market like cell therapy are growing rapidly. The ability to use a patient’s own cells to treat and even cure disease is revolutionizing the future of modern medicine, leading to exciting discoveries and novel treatments. However, the specificities of bringing these products to market are creating significant challenges for drug manufacturers that must be overcome in order to realize the true potential of cell therapies. One approach that can aid in overcoming these bottlenecks is leveraging the experience of those already tackling the complexities of cell therapy manufacturing.
Dr. Carolyn Wrightson, Chief Technical Officer of Cellipont Bioservices (formerly Performance Cell Manufacturing), and her team pioneered the historical development of an autologous canine mesenchymal stem-cell (MSC) product as well as human mesenchymal stem-cell drug product manufacture. Here she shares some of the valuable lessons and considerations she and her team learned about stem cell therapy scale-up and optimization.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.